Skip to main content

Table 1 Clinical and Histopathological Characteristics in 175 Patients With ESCC Treated With Neoadjuvant therapy Plus Surgical Resection

From: Prognostic value of visual residual tumour cells (VRTC) for patients with esophageal squamous cell carcinomas after neoadjuvant therapy followed by surgery

 

n

Percent (%)

tumour regression grade (Becker)

tumour regression grade (Japan)

TRG 1a-1b

%

P value

Grade 2–3

%

P value

Age

    

0.168

  

0.231

 < 60

80

45.7

24

30.0

 

34

42.5

 

 ≥60

95

54.3

38

40.0

 

49

51.6

 

Gender

    

0.530

  

0.935

 Female

27

15.4

11

40.7

 

13

48.1

 

 Male

148

84.6

51

34.5

 

70

47.3

 

Anatomic location

    

0.118

  

0.221

 Upper third

29

16.6

15

51.7

 

18

62.0

 

 Middle third

82

46.9

25

30.5

 

37

45.1

 

 Lower third

64

36.6

22

34.4

 

28

43.8

 

Size

    

0.004

  

< 0.001

 < 3 cm

90

51.4

41

45.6

 

58

64.4

 

 ≥3 cm

85

48.6

21

24.7

 

25

29.4

 

Lymphovascular invasion

    

< 0.001

  

< 0.001

 Negative

118

67.4

59

50.0

 

70

59.3

 

 Positive

57

32.6

3

5.3

 

13

22.8

 

Perineural growth

    

< 0.001

  

< 0.001

 Negative

119

68.0

58

48.7

 

73

61.3

 

 Positive

56

32.0

4

7.1

 

10

17.9

 

Lymph-node metastasis

    

< 0.001

  

< 0.001

 Negative

92

52.6

46

50.0

 

57

62.0

 

 Positive

83

47.4

16

19.3

 

26

31.3

 

ypN-stage

    

< 0.001

  

< 0.001

 ypN0

92

52.6

46

50.0

 

57

62.0

 

 ypN1

51

29.1

12

30.8

 

20

39.2

 

 ypN2

23

13.1

4

17.4

 

6

26.1

 

 ypN3

9

5.1

0

0

 

0

0

 

Type of neoadjuvant

    

< 0.001

  

< 0.001

 Chemotherapy

108

61.7

23

21.3

 

30

27.8

 

 Chemoradiotherapy

67

38.3

39

58.2

 

53

79.1

 

tumour regression grade (Becker)

 TRG1a

26

14.9

      

 TRG1b

36

20.6

      

 TRG2

33

18.9

      

 TRG3

80

45.7

      

tumour regression grade (Japan)

 G0-1a

64

36.6

      

 G1b

28

16.0

      

 G2

57

32.6

      

 G3

26

14.9

     Â